Abstract Sequence-based testing of disease-susceptibility genes has identified many variants of unknown significance (VUSs) whose pathogenicity is unknown at the time of their measurement. Female breast cancer cases aged 20-49 years at diagnosis and who have VUSs in BRCA1 and no mutations in BRCA2 have previously been identified through the population-based Los Angeles County Cancer Surveillance Program. These nominal BRCA1 VUSs have been classified as ''low,'' ''medium,'' and ''high'' risk by four classification methods: Align-GVGD, Polyphen, Grantham matrix scores, and sequence conservation in mammalian species. Average hazard ratios (HRs) for classes of variants, i.e., the age-specific incidences of cancer for carriers of such variants divided by the population incidences, were estimated from the cancer family histories of first-and second-degree relatives of the index cases using modified segregation analysis. The study sample comprised 270 index cases and 4,543 of their relatives. There was weak evidence that the risk of breast cancer increases with the degree of sequence conservation (P = 0.03) and that missense variants at highly conserved sites are associated with a 5.6-fold (95 % confidence interval 1.4-22.2; P = 0.05) increased incidence of breast cancer. An upper bound of 2.3 is given for the average breast cancer HRs corresponding to variants classified as ''low risk'' by any of the four VUS classification methods. In summary, we have given a method to estimate cancer risks for groups of VUSs by combining existing classification methods with traditional penetrance analyses. This analysis suggests that classification methods for BRCA1 variants based on sequence conservation might be useful in a clinical setting. We have shown in principle that our method can be used to classify VUSs into clinically useful risk categories, but our specific findings should not be put into clinical practice unless confirmed by larger studies.
Introduction
Sequence-based testing of high-risk disease-susceptibility genes in clinical and research contexts usually identifies a large number of genetic variants which are neither clearly pathogenic nor clearly benign [1, 2] . Carriers of such variants of unknown significance (VUSs) cannot be given definite information about their risks of disease, and the appropriate clinical management of such carriers is debatable.
Most VUSs are missense variants which result in the change of a single amino acid in the protein product of the gene [1, 2] . The occurrence of a VUS in a series of multiple-case families does not imply that the VUS confers a high risk of disease unless it is known that the VUS occurs more rarely in comparable families without family histories of the disease. Some VUSs are sufficiently common that their associated risks of disease can be estimated but most VUSs are rare, so direct risk estimates are not possible [3] [4] [5] .
A number of methods exist to predict the pathogenicity of individual VUSs based on the predicted effect of the variant on the encoded protein [6, 7] and/or the level of sequence conservation at the variant's homologous sites in non-human species [8, 9] . These classification methods can be used to classify individual VUSs into nominally ''low,'' ''medium,'' or ''high'' risk categories, but the actual disease risks conferred by variants in these categories are unknown.
In this paper, we use penetrance analysis to estimate the average risks of disease associated with certain classes of VUSs, such as the set of all VUSs classified as ''high risk'' by a given method. We suggest that, in the absence of further information about an individual VUS, such average risks can be used for the genetic counseling and clinical management of a carrier of any VUS in the class. This is in line with current clinical practice for deleterious mutations, because even though disease risks might vary from mutation to mutation, the genetic counseling and clinical management of carriers is uniform across this class of variants and is based on average risks obtained from pooled analyses of families with different mutations. We focus on the gene BRCA1 (OMIM 113705) and the diseases breast and ovarian cancer in this paper, but our approach can easily be applied to other genes and diseases.
Materials and methods

Subjects
Data collection methods used in conducting the Women's Learning the Influence of Family and Environment Study have previously been described [10] . In brief, female patients diagnosed with histologically-confirmed first primary invasive breast cancer were identified through the Los Angeles County Cancer Surveillance Program, a population-based Surveillance, Epidemiology and End Results registry supported by the State of California and the National Cancer Institute. Eligible cases were (1) USborn and English speaking, (2) white (including Latina) or African-American, (3) aged 20-49 years at diagnosis, and (4) Los Angeles County residents at diagnosis. A total of 2,882 eligible cases were identified (2,534 whites and 348 African-Americans) between February 1998 and May 2003. Recruitment of African-Americans began after the initiation of the study with eligible African-American cases diagnosed from January 2000 to May 2003.
Among the 2,882 potentially eligible cases, 1,794 (62 %) were interviewed (1,585 white, 209 AfricanAmerican). Reasons for non-participation were patient refusal (n = 428), no longer a resident of Los Angeles County (n = 37), not located (n = 88), death (n = 38), serious illness or disability (n = 18), physician refusal (n = 50), or inability to schedule the interview within 18 months of diagnosis (n = 429). The original study was approved by the Institutional Review Board of the University of Southern California (USC). All participants provided written informed consent.
Data and blood specimen collection An in-person interview was completed using a modified version of the structured questionnaire used in the Women's Contraceptive and Reproductive Experiences Study [11] . The questionnaire included detailed information on demographic characteristics, detailed family history of breast or ovarian cancer, ethnic origin, and environmental factors such as oral contraceptive use, reproductive history, alcohol use, smoking history, and radiation exposure. We obtained information up to the date of breast cancer diagnosis. Blood specimens were collected from 1,519 participants (85 %) and transported to the USC Norris Comprehensive Cancer Center Genetics Core Laboratory in Styrofoam containers on frozen ice packs. For the first 50 samples, buffy coat was immediately extracted and stored, and for the remaining samples we stored whole blood.
Sequencing of BRCA1 and BRCA2 and classification of variants
The sequencing of BRCA1 and BRCA2 (OMIM 600185) and the classification of the resulting variants have been described previously [9] . In brief, all BRCA1 and BRCA2 exons (except BRCA1 exons 1 and 4 and BRCA2 exon 1) as well as all exon-intron boundaries were sequenced. Exon 1 was not sequenced for either gene because it is located upstream of the translation start site in both genes. BRCA1 exon 4 was not sequenced because it is not found in the normal BRCA1 mRNA transcript. DNA extraction, amplification, and sequencing were done in the USC Genomics Core Laboratory using a protocol similar to that previously described [12] . We sequenced BRCA1 and BRCA2 for 1,469 out of 1,519 blood specimens. We were unable to sequence the remaining 50 specimens due to insufficient DNA. Thirty-three randomly selected, blinded samples were re-sequenced for quality control purposes. The discordance was 0.19 %: 16 discordant sequencing results out of the total 8,646 variant sites sequenced (262 variant sites for each of the 33 samples). In addition, 166 subjects who had non-informative sequencing results on one or more variant sites were re-sequenced or genotyped using TaqMan assay (for I2490T, N372H, and N991D) as previously described [13] .
BRCA1 and BRCA2 variants were first classified into one of the following categories: (1) definitely diseasecausing variants, including frameshift mutations, nonsense mutations, splice variants that were previously reported to affect splicing or located at the exon/intron boundary, and missense variants that were previously shown to be deleterious; (2) VUSs, including in-frame deletion/insertions, intronic variants that might affect splicing by creating a splice donor/acceptor site, variants next to the exon/intron boundary, and most missense variants; or (3) benign polymorphic variants, including synonymous variants, intronic variants that are unlikely to affect splicing, and a few missense mutations that have been reported to be benign. See [9] for a list of all variants identified in this study with their classification and reasons and references for such classification.
Restriction to women carrying VUSs in BRCA1 and not carrying mutations in BRCA1 or BRCA2
Of the 1,469 cases whose BRCA1 and BRCA2 genes were sequenced, 984 carried a VUS in BRCA1 or BRCA2, as described previously [9] . In the present study, we excluded cases carrying only polymorphisms in BRCA1 (n = 627), any DDCV in BRCA1 (n = 41) or BRCA2 (n = 9), and any splice variant or in-frame deletion in BRCA1 (n = 6) or BRCA2 (n = 2). We further excluded cases with noninformative genetic test results at any DDCV or VUS site in BRCA1 (n = 16) or BRCA2 (n = 13), giving a final dataset of 270 cases and their families.
Classification methods for BRCA1 VUSs
All BRCA1 VUSs were classified with the following methods, as described previously [9] (with the exception of A-GVGD):
1. Sequence conservation BRCA1 homologues in 10 mammalian species were used to measure the degree of sequence conservation of each site of BRCA1.
Variants at sites which are conserved in 9-10, 7-8, or six or less of these ten species were, respectively, considered to be the ''high,'' ''medium,'' or ''low'' risk variants of this method. 2. Grantham matrix score (GMS) [6] . Using a criterion used previously to define neutral missense variants [14] , those with GMS less than 60 were considered the ''low risk'' variants of this method. All other variants were classified as ''high risk.'' 3. A-GVGD [8] . The ''high,'' ''medium,'' and ''low'' risk variants of this method were (respectively) those classified by A-GVGD as C45 or higher, C15-C35, or less than C15. 4. Polyphen [7] . Variants classified as ''probably damaging,'' ''possibly damaging,'' and ''benign'' by the PolyPhen algorithm were, respectively, considered to be ''high,'' ''medium,'' or ''low'' risk.
Statistical methods
For various groups of VUSs, the corresponding average hazard ratios (HRs) for breast and ovarian cancer, i.e., the age-specific incidence of cancer for women with VUSs in the given class divided by the appropriate population incidence, were estimated by modified segregation analysis [15, 16] . Models were fitted by the method of maximum likelihood with the likelihood for each pedigree given by Ott's form [16] in which the penetrance function was based on a parametric survival model. More specifically, the (unconditional) likelihood of each pedigree was assumed to have the following form:
where h is the vector of unknown log HRs to be estimated; g is a vector specifying genotypes for all family members; the sum is over all genotypes consistent with the index case's genotype; P(g) is the joint probability of the family's genotypes g; the product is over all individuals i in the family; x i is a vector specifying all phenotypic data for person i, consisting of his or her affected status and an age t i equal to the age of diagnosis (if affected) or last known age (if unaffected); g i is the genotype of person i according to the vector g; either P(x i |g i ) = S(t i |g i ) if individual i is unaffected or P(x i |g i ) = k(t i |g i )S(t i |g i ) if individual i is affected; S(t i |g i ) is the survival function for genotype g i evaluated at age t i years, equal to exp(-$k(t|g i ) dt) where the terminals of integration are 0 and t i ; k(t i |g i ) is the hazard evaluated at age t i years, equal to k(t i |g i ) = HR(g i ) k(t i ); and k(t i ) is the age-standardized and age-, sex-, and racespecific population incidence rate By design, each index case was affected and carried a VUS, so in order to avoid ascertainment bias due to this study design, the likelihood of each family was conditioned on the index case's BRCA1 VUS genotype, the fact that she was a breast cancer case and her age at onset [17, 18] . The underlying genetic model used by the segregation analysis was a mixed model which incorporated a polygenic background, implemented via a hypergeometric polygenic model [15, 19] [20] ), in addition to the BRCA1 major gene locus. HRs were assumed to be constant with age and each woman within each family was assumed to either have a polymorphism at the BRCA1 locus (with HR = 1) or an identical-by-descent copy of the index case's VUS. Population breast and ovarian cancer incidence rates were sex-, age-, and race-specific (race being white/black) for the US population 1989-93 and were taken from Tables IV-2 and XX-2 of SEER Cancer Statistics Review 1973-1993 [21] .
In the main analyses, average HRs were estimated for all variants placed into particular risk groups by particular classification methods. More detailed analyses were performed based on the raw (non-dichotomized) GMS, the number of mammalian species (out of the 10 considered) for which the site of the variant was conserved and the number of classification methods (out of four) which classified the given VUS as ''high risk.'' Tests for trend between cancer risks and these variables assumed a linear dependence between the log HR and the given variable, with the log HR fixed to zero in these analyses for (respectively) VUSs with GMS equal to zero, VUSs at sites conserved in seven species or less, and VUSs classified as ''high risk'' by zero models.
Affected relatives of the index cases with missing ages at diagnosis (comprising 10 % of breast cancer diagnoses and 11 % of ovarian cancer diagnoses) were included in the analysis by marginalizing over the missing ages and maximizing the resulting likelihood. Unaffected relatives with missing ages (comprising 15 % of all unaffected females) were censored at birth, effectively removing them from the analysis, since their affected statuses were considered to be unreliable.
Standard errors were obtained by inverting the observed Fisher information matrix, while P values were calculated from likelihood ratio tests. Segregation analyses were performed with Mendel [22] 
Results
Among 1,469 index cases who were sequenced for BRCA1 and BRCA2, 270 had a BRCA1 VUS and did not have a BRCA1 or BRCA2 mutation; 29 (11 %) of these cases were black and 241 (89 %) were white (including Latina white). The first-and second-degree relatives of these index cases comprised 2,258 (50 %) females and 2,285 (50 %) males. Of the female relatives, 164 (7 %) had been diagnosed with first primary breast cancer and 23 (1 %) with ovarian cancer. Table 1 gives the number of breast and ovarian cancer diagnoses in the female relatives of the index cases, broken down by the risk class of the index case's VUS according to the different classification methods.
For each VUS, we counted the number of methods which classified the variant as ''high risk,'' giving a whole number between zero and four which summarizes the classifications of all methods. There was no evidence that the risk of cancer increased with this number for either breast (P = 0.09) or ovarian (P = 0.4) cancer.
For each classification method, Table 2 gives the average HR for all VUSs classified as ''high,'' ''medium,'' or ''low'' risk by the given method. There was weak evidence that missense variants at highly conserved sites are associated with an increased risk of breast cancer (P = 0.05), with breast cancer incidences for carriers of such VUSs estimated to be 5.6 (95 % CI: 1.4-22.2) times the population incidences. Otherwise, our data were consistent with the average HR for each class of VUS being 1 for breast cancer (all P C 0.2) and ovarian cancer (all P C 0.3). The 95 % confidence intervals for these HR estimates show that the true incidences of breast cancer for VUSs in the ''low risk'' category of any classification method are likely to be less than 2.3 times the population incidences, on average. The corresponding ovarian cancer HR estimates are far less precise than those for breast cancer so the corresponding confidence intervals do not give useful upper bounds for the true HR.
Last, we investigated whether risk depended on the degree of sequence conservation at the site of the VUS or on the VUS's Grantham matrix score. No evidence was observed that breast or ovarian cancer risks varied with the Grantham matrix score, with each 50 point increase in the Grantham matrix score associated with an estimated increase in cancer incidence by a factor of 1.4 (95 % CI 0.89-2.1; P = 0.2) for breast and 1.3 (95 % CI 0.60-3.0; P = 0.6) for ovarian cancer. There was also no evidence that ovarian cancer risk depended on the VUS's level of sequence conservation (P = 0.5) but the risk of breast cancer increased with the amount of sequence conservation (P = 0.03). Table 3 gives the HRs for VUS with various levels of sequence conservation.
Discussion
We have shown that it is possible to estimate cancer risks for groups of VUSs by combining existing classification methods with traditional penetrance analyses. The estimated HRs give the average risks for all variants placed into a given risk class by a given classification method, just as estimated HRs for deleterious mutations are the average across the class of all such variants. We suggest that, in the absence of information about an individual VUS other than its nominal predictive risk class, such average risks can be used for the genetic counseling and clinical management of a carrier of any VUS in the class. They constitute the best evidence available, just as an estimate of average risk for the group of protein-truncating mutations is the best evidence available for counseling those carriers, even though their specific mutation might never have been previously observed. Application of this method to BRCA1 and breast and ovarian cancer risks found weak evidence that missense variants at highly conserved sites are associated with an increased risk of breast cancer (P = 0.05). It also showed that the risk of breast cancer increases with the degree of sequence conservation (P = 0.03). This analysis also suggested that variants in the ''high risk'' category of A-GVGD have risks close to those of deleterious mutations, although the confidence interval for this estimate was too wide to draw definite conclusions, so these results should not be put into clinical practice unless confirmed by larger studies.
We also showed that female carriers of variants classified as ''low risk'' by a given classification method have, on average, incidences of breast cancer likely to be less than twice the population incidences (and possibly no higher than the population incidences). This upper bound provides some certainty and reassurance to the vast majority of female VUS carriers whose VUSs are classified as ''low risk'' by a given classification method.
Our study is similar to that of Akbari et al. [24] , who used Cox proportional hazards to estimate cancer risks for the first-degree relatives of ovarian cancer cases (unselected for a family history of cancer) by comparing the relatives of VUS carriers to those of polymorphism carriers. Their method therefore estimates the relative risk associated with having a VUS-carrying first-degree relative, while our HR hazard ratio, CI confidence interval, NE not estimable due to low numbers method estimates the risk associated with personally carrying a VUS. Since on average half of the first-degree relatives of VUS carriers will not carry a VUS, the HRs obtained by Akbari et al. [24] should be approximately equal to (1 ? h)/2, where h is the HR associated with personally carrying the VUS, as estimated in this paper. Therefore, their estimate of h for breast, ovarian, and fallopian tube cancers (combined) for ''high risk'' A-GVGD VUSs is about 2*5.24-1 = 9.5. Encouragingly, this is similar to our estimate of 8.3 (0.83-83.0) for breast cancer (which should dominate their combined class of cancers, since it is by far the most common cancer), though the wide confidence intervals on our estimate and theirs means that this near agreement could be due to chance. Relative strengths of our method over that of Akbari et al. [24] include our direct estimation of the main quantity of interest, h, our ability to rigorously adjust for complex ascertainment schemes, and our ability to reduce bias in penetrance estimates [18] by incorporating residual familial aggregation of cancer. Our estimates quantify the effect of the VUS on top of an unmeasured polygenic background of breast cancer risk. Including a polygenic background was necessary because simulation has shown that failure to use a mixed model or to otherwise account for residual familial aggregation of risk can bias penetrance estimates [18] . Since the polygenic background can be thought of as capturing a woman's family history of cancer, her incidence of breast cancer should be calculated as the relevant HR for her VUS multiplied by both the population incidence and a factor reflecting her family history, e.g., a factor of approximately two if she has an affected first-degree relative.
Strengths of our study include the population-based study design and the powerful and rigorous statistical methods used. Weaknesses include the fact that, for each VUS classification method, relatively few families had VUSs that were classed as ''high risk,'' leading to imprecision in the resulting HR estimates. This problem was exacerbated by the relative rarity of ovarian cancer, giving us little statistical power to detect increased risks for this disease.
In summary, we have described a method to estimate cancer risks for groups of VUSs by combining existing classification methods with traditional penetrance analyses. This analysis suggests that classification methods for BRCA1 variants based on sequence conservation might be useful in a clinical setting and that, on average, variants classed as ''low risk'' increase breast cancer risks by at most a moderate amount. We have shown in principle that our method can be used to classify VUSs into clinically useful risk categories, but our specific findings should not be put into clinical practice unless confirmed by larger studies.
